Soligenix (SNGX) Total Non-Current Liabilities (2012 - 2016)
Soligenix's (SNGX) quarterly Total Non-Current Liabilities came in at $6.4 million in Q3 2016, up 52.5% YoY from $4.2 million in Q4 2015, and up 50.65% on a QoQ basis from $4.3 million in Q2 2016.
Soligenix (SNGX) Total Non-Current Liabilities (2012 - 2016) Analysis & Trends
Soligenix (SNGX) has 5 years of Total Non-Current Liabilities data on file, last reported at $6.4 million in Q3 2016.
- Quarterly Total Non-Current Liabilities rose 52.5% year-over-year to $6.4 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $6.4 million (up 52.5% YoY) and the FY2015 annual result came in at $5.0 million, up 56.51% from the prior year.
- Total Non-Current Liabilities climbed to $6.4 million in Q3 2016, from $4.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $6.4 million in Q3 2016 to a low of -$2.6 million in Q2 2014.
- A 5-year average of $1.6 million and a median of $2.0 million in 2012 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 6603.71% in 2014, down 164.17% in 2014.
- Tracing SNGX's Total Non-Current Liabilities over 5 years: stood at $2.0 million in 2012, then plunged by 97.67% to $47208.0 in 2013, then soared by 6603.71% to $3.2 million in 2014, then soared by 56.51% to $5.0 million in 2015, then grew by 29.8% to $6.4 million in 2016.
- The last three Total Non-Current Liabilities figures came in at $6.4 million (Q3 2016), $4.3 million (Q2 2016), and $3.9 million (Q1 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 6.43 Mn |
| Jun 30, 2016 | 4.27 Mn |
| Mar 31, 2016 | 3.92 Mn |
| Dec 31, 2015 | 4.95 Mn |
| Sep 30, 2015 | 4.22 Mn |
| Jun 30, 2015 | -835,366.00 |
| Mar 31, 2015 | 750,290.00 |
| Dec 31, 2014 | 3.16 Mn |
| Sep 30, 2014 | -1.16 Mn |
| Jun 30, 2014 | -2.63 Mn |
| Mar 31, 2014 | -2.51 Mn |
| Dec 31, 2013 | 47,208.00 |
| Sep 30, 2013 | -2.33 Mn |
| Jun 30, 2013 | 4.10 Mn |
| Dec 31, 2012 | 2.02 Mn |